021-51111890
购物车（）
sales@molnova.cn
Pomalidomide-PEG4-C2-NH2
CAS No. 2225940-52-1
Pomalidomide-PEG4-C2-NH2 ( Cereblon Ligand-Linker Conjugates 8; E3 Ligase Ligand-Linker Conjugates 22 )
产品货号. M26946 CAS No. 2225940-52-1
Pomalidomide-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate incorporating the Pomalidomide-based cereblon ligand and 4-unit PEG linker.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥389 | 有现货 |
|
| 5MG | ￥632 | 有现货 |
|
| 10MG | ￥948 | 有现货 |
|
| 25MG | ￥1588 | 有现货 |
|
| 50MG | ￥2365 | 有现货 |
|
| 100MG | ￥3686 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Pomalidomide-PEG4-C2-NH2
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Pomalidomide-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate incorporating the Pomalidomide-based cereblon ligand and 4-unit PEG linker.
-
产品描述Pomalidomide-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate incorporating the Pomalidomide-based cereblon ligand and 4-unit PEG linker.
-
同义词Cereblon Ligand-Linker Conjugates 8; E3 Ligase Ligand-Linker Conjugates 22
-
通路Others
-
靶点Other Targets
-
受体Glucocorticoid Receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number2225940-52-1
-
分子量492.5
-
分子式C23H32N4O8
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESNCCOCCOCCOCCOCCNc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Lorscheider M, et al. Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis. J Control Release. 2019 Feb 28;296:179-189.
产品手册
关联产品
-
Kaempferol 7-O-rutin...
The fruits of Citrus reticulata.
-
Martynoside
Martynoside is a natural selective estrogen receptor modulator, which has antioxidative, anti-muscle fatigue, anticancer and antimetastatic activities.
-
TLQP-30
Chronic intracerebroventricular (ICV) injection of a VGF peptide named TLQP-21 increased resting energy expenditure and temperature in mice. Furthermore, in mice fed a high-fat diet, the same peptide prevented the increase in body and white adipose tissue (WAT) weight as well as hormonal changes associated with a high-fat regimen.
